BDNF and schizophrenia: Secondly, in the aforementioned human post-mortem brain studies of schizophrenia, changes in BDNF protein and mRNA expression were attributed to schizophrenia pathophysiology and not to antipsychotic treatment based on (1) the lack of correlation between BDNF expression with last dose, average daily dose and lifetime equivalents of chlorpromazine or fluphenazine (27–29, 31, 35), (2) clinical records and familial report, post-mortem toxicology of blood or brain tissue (31), or the (3) lack of effect of haloperidol administration in rodents (33) and monkeys (12).